Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Aalborg Hospital |
---|---|
Information provided by: | Aalborg Hospital |
ClinicalTrials.gov Identifier: | NCT00488904 |
To discover whether an Omega-3 fatty acid (eicosapentaenoic acid/EPA and docosahexaensyre/DHA) enriched nutritional supplement given 7 days preoperatively and 7 days postoperatively may reduce the frequency of postoperative infectious complications defined as: pneumonia, wound infection, urinary tract infection, peritonitis (including anastomotic leakage) and septic conditions of any cause in patients who undergo elective operations for colorectal cancer compared with a nutritional preparation that is identical apart from the EPA content.
Condition | Intervention | Phase |
---|---|---|
Colorectal Cancer |
Dietary Supplement: supportan Dietary Supplement: supportan placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Omega-3 Fatty Acids and Postoperative Complication After Colorectal Surgery |
Estimated Enrollment: | 140 |
Study Start Date: | June 2007 |
Estimated Study Completion Date: | July 2009 |
Estimated Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
a: Experimental |
Dietary Supplement: supportan
2 sip feed pr. day
|
b: Placebo Comparator |
Dietary Supplement: supportan placebo
2 sip feed pr. day
|
Several earlier studies indicate that perioperative supplements of Omega-3 fatty acids can reduce the risk of postoperative complications after major surgery through an immune modulating effect in the form of a downward adjustment of the inflammatory response. (1-7) The interpretation of these studies is made more difficult by differences in their method of administration (parentally/enterally), differences in the time of the intervention (preoperative/postoperative) and differences in the selection of patients (malnourished cancer patients / upper GI cancer patients/mixed surgical patients) and finally because many of the studies deal with a so-called immune modulating preparation containing a mixture of arginine, Omega-3 fatty acids and ribonucleic acid. The biological effects of fish oils are related to their content of such things as Omega-3 fatty acids that can be incorporated in cell membranes where they influence receptor function, enzyme activity and the production of lipid mediators. The cells from the immune system perform their functions through membrane-associated activities like secretion of cytokines, antibodies, lymphocyte transformation and contact lysine. These functions can be affected by changes in the membrane structure. (7;8) Besides the effect parameter of postoperative septic complications, many of these studies use pseudoparameters such as length of stay, need for respirator treatment, time in intensive care as well as a wide range of biochemical changes whose relevance to the clinic process can be difficult to assess. (1-7;9-13;). It is well-known that early enteral nutrition reduces the risk of postoperative complications (14; 15). Many of the aforementioned studies similarly point to a benefit from using Omega-3 fatty acid enriched nutritional preparations preoperatively. There is now a commercially manufactured nutritional preparation for peroral consumption containing Omega-3 fatty acids - Supportan (Fresenius-Kabi). The preparation is more energy intensive than similar drink preparations, but does not otherwise differ in composition from standard preparations. It is approved by the Danish Veterinary and Food Administration for this study. In 2 x 200ml of Supportan 3 g EPA and DHA are given daily. In other studies up to 10 g have been given daily without side effects. (6; 16)
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Lone sc Sørensen, consultant | 45-8695-4145 | lss@mail.dk |
Contact: Karen lindorfflarsen, consultant | 45-9932-1111 | kgll@rn.dk |
Denmark | |
Aalborg Hospital | Recruiting |
Aalborg, Denmark, 9000 Aalborg | |
Contact: Lone Sc Sørensen, registra 45-8695-4145 lss@mail.dk | |
Contact: Karen lindorff-larsen, consultant 45-9932-1111 kgl@rn.dk | |
Principal Investigator: Lone Sc Sørensen, registra |
Study Director: | Erik be schmidt, professor | Aalborg Hospital the lipid clinic |
Responsible Party: | Fresenius Kabi ( Lone Schmidt Sørensen ) |
Study ID Numbers: | 123omega, VN2005/35 |
Study First Received: | June 19, 2007 |
Last Updated: | July 31, 2009 |
ClinicalTrials.gov Identifier: | NCT00488904 History of Changes |
Health Authority: | Denmark: National Board of Health; Denmark: Danish Dataprotection Agency |
infection colorectalcancer omega-3 fedtsyre complications |
Digestive System Diseases Digestive System Neoplasms Postoperative Complications Gastrointestinal Diseases Omega 3 Fatty Acid Colonic Diseases |
Gastrointestinal Neoplasms Intestinal Diseases Rectal Diseases Intestinal Neoplasms Colorectal Neoplasms |
Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Intestinal Neoplasms Neoplasms |
Neoplasms by Site Digestive System Diseases Pathologic Processes Postoperative Complications Gastrointestinal Neoplasms Colorectal Neoplasms |